Dr. Reddy’s Laboratories (NYSE:RDY) Getting Very Favorable Press Coverage, Accern Reports
Press coverage about Dr. Reddy’s Laboratories (NYSE:RDY) has trended very positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dr. Reddy’s Laboratories earned a coverage optimism score of 0.70 on Accern’s scale. Accern also assigned news articles about the company an impact score of 50 out of 100, meaning that recent news coverage is somewhat likely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Dr. Reddy’s to Release Q1 FY18 Results on July 27, 2017 – Business Wire (press release) (businesswire.com)
- Zacks Investment Research Upgrades Dr. Reddy’s Laboratories Ltd (RDY) to Hold (americanbankingnews.com)
- Dr. Reddy’s Laboratories Ltd (RDY) Position Up in Latest Report from Fisher Asset Management, LLC Last Quarter – Highlight Press (highlightpress.com)
- Horizon Pharma patents covering Vimovo arthritis pain relief treatment have validity upheld at district court and PTAB – IPWatchdog.com (ipwatchdog.com)
Shares of Dr. Reddy’s Laboratories (NYSE:RDY) opened at 41.86 on Monday. The firm has a 50 day moving average price of $40.51 and a 200-day moving average price of $42.25. Dr. Reddy’s Laboratories has a 12 month low of $37.03 and a 12 month high of $54.58. The company has a market cap of $6.94 billion, a P/E ratio of 37.64 and a beta of 0.35.
The company also recently disclosed a dividend, which will be paid on Monday, July 17th. Stockholders of record on Monday, July 17th will be issued a dividend of $0.29 per share. The ex-dividend date is Thursday, July 13th. Dr. Reddy’s Laboratories’s dividend payout ratio is presently 26.61%.
A number of analysts have commented on RDY shares. Deutsche Bank AG upgraded Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Monday, May 15th. Zacks Investment Research upgraded Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday. Three analysts have rated the stock with a sell rating and two have given a hold rating to the company. The company presently has a consensus rating of “Sell” and an average price target of $41.90.
TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/dr-reddys-laboratories-nyserdy-getting-very-favorable-press-coverage-accern-reports/1445217.html.
Dr. Reddy’s Laboratories Company Profile
Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).
Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.